此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

西格列他/二甲双胍缓释片食物影响及多次给药研究

2026年11月3日 更新者:Chipscreen Biosciences, Ltd.

评估西格列他/二甲双胍缓释固定剂量复方片食物效应及多剂量药代动力学的I期临床研究

This trial includes two parts: a food effect (FE) study and a multiple-dose pharmacokinetic (PK) study.

The FE study is a randomized, open-label, two-period, two-sequence crossover study designed to evaluate the effect of a high-fat meal on the PK of a single oral dose of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants.

The multiple-dose PK study is an open-label study designed to evaluate the PK characteristics of Chiglitazar/Metformin extended-release tablets in healthy adult Chinese participants following multiple oral doses.

研究概览

研究类型

介入性

注册 (实际的)

28

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、101300
        • Beijing Ditan Hospital, Capital Medical University

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 45年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy male or female participants;
  • Age from 18 to 45 years, inclusive;
  • Body Mass Index (BMI) between 19.0 and 26.0 kg/m² (inclusive). Male participants must weigh at least 50.0 kg, and female participants must weigh at least 45.0 kg;
  • From the time of signing the informed consent form until 3 months after the last dose, participants must have no plans for pregnancy or sperm donation and must be willing to use effective contraceptive measures;
  • Voluntarily agrees to participate in the study and signs the informed consent form.

Exclusion Criteria:

  • Any clinically significant abnormalities in laboratory tests or a history of clinically significant diseases, including but not limited to cardiovascular, cerebrovascular, hepatic, renal, respiratory, gastrointestinal, neurological, hematological, immune, oncological, psychiatric, or endocrine/metabolic disorders;
  • Known history of severe allergies (e.g., allergy to more than 3 allergens, allergies affecting the lower respiratory tract such as allergic asthma, allergies requiring glucocorticoid treatment) or a known history of allergy to any component of the investigational products;
  • Previous surgery that could affect drug absorption, distribution, metabolism, or excretion (e.g., subtotal gastrectomy), or a history of gastrointestinal, hepatic, or renal disease within the last 6 months that could affect drug absorption or metabolism;
  • Surgery within 3 months prior to screening or planned surgery during the study period;
  • Received any vaccination within 1 month prior to screening or plan to receive any vaccination during the study period;
  • History of infectious disease treated with significant use of antibiotics within 3 months before the first dose, or any infectious disease within 7 days before the first dose;
  • Presence of gastrointestinal symptoms (e.g., diarrhea, constipation, nausea, vomiting) within 7 days before the first dose, which the investigator deems unsuitable for study participation;
  • Use of any prescription drugs, over-the-counter drugs, or Chinese herbal medicines within 1 month before the first dose; or use of vitamin products within 2 weeks before enrollment;
  • History of drug or substance abuse, or a positive alcohol or urine drug screening test;
  • Intolerance to venipuncture, or a history of fainting in response to needles or blood;
  • Fasting blood glucose > 6.1 mmol/L or < 3.9 mmol/L at screening, and/or a history of hypoglycemia/syncope;
  • Participation in any interventional clinical trial within 3 months prior to screening;
  • Blood donation or significant blood loss (> 200 mL) within 3 months prior to screening;
  • Pregnant or lactating women;
  • Weekly alcohol consumption of more than 14 units within 3 months prior to screening, consumption of alcohol within 48 hours before the first dose, or inability to abstain from alcohol during the study;
  • Smokes more than 5 cigarettes per day within 3 months prior to screening, has smoked within 48 hours before the first dose, or is unable to abstain from smoking during the study;
  • Excessive daily consumption of tea, coffee, and/or caffeinated beverages within 3 months prior to screening, or consumption of such beverages within 48 hours before the first dose;
  • Consumption of grapefruit or grapefruit-related citrus fruits (e.g., Seville oranges, pomelos), star fruit, papaya, pomegranate, or their products within 14 days before the first dose;
  • Glomerular Filtration Rate (GFR) < 90 mL/min/1.73 m²;
  • Systolic blood pressure < 90 mmHg or ≥ 140 mmHg, or diastolic blood pressure < 50 mmHg or ≥ 90 mmHg at screening;
  • Inability to comply with the standardized diet (e.g., intolerance to the high-fat meal, lactose intolerance) or has difficulty swallowing;
  • Plans to or is required to engage in strenuous physical activity or exercise during the study period;
  • Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:FE研究序列1

a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions

a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal

实验性的:FE研究第2序列

a single dose of Chiglitazar/Metformin extended-release tablets under fasting conditions

a single dose of Chiglitazar/Metformin extended-release tablets after a high-fat meal

实验性的:多剂量组

a single dose on Day 1, once-daily consecutive doses from Day 4 to Day 10

研究衡量的是什么?

主要结果指标

结果测量
大体时间
FE研究:最大血浆浓度(Cmax)
大体时间:给药前及给药后72小时内多个时间点
给药前及给药后72小时内多个时间点
FE研究:血浆浓度-时间曲线下面积(AUC)
大体时间:给药前及给药后多个时间点(最长72小时)
给药前及给药后多个时间点(最长72小时)
FE研究:达峰时间(Tmax)
大体时间:给药前以及给药后72小时内的多个时间点
给药前以及给药后72小时内的多个时间点
FE研究:消除半衰期(t1/2)
大体时间:给药前以及给药后72小时内多个时间点
给药前以及给药后72小时内多个时间点
FE 研究:表观总清除率 (CL/F)
大体时间:给药前以及给药后72小时内多个时间点
给药前以及给药后72小时内多个时间点
FE研究:终末期的表观分布容积(Vz/F)
大体时间:给药前及给药后至72小时内的多个时间点
给药前及给药后至72小时内的多个时间点
多次给药药代动力学研究:最大血浆浓度(Cmax)
大体时间:给药前至末次给药后72小时(连续给药7天)
给药前至末次给药后72小时(连续给药7天)
多剂量药代动力学研究:血浆浓度-时间曲线下面积(AUC)
大体时间:末次给药前至给药后72小时(连续给药7天)
末次给药前至给药后72小时(连续给药7天)
多次给药药代动力学研究:达峰时间(Tmax)
大体时间:末次给药前至末次给药后72小时(连续给药7天)
末次给药前至末次给药后72小时(连续给药7天)
多次给药药代动力学研究:稳态峰值浓度(Cmax,ss)
大体时间:末次给药前至给药后72小时(连续7天给药)
末次给药前至给药后72小时(连续7天给药)
多剂量药代动力学研究:稳态达峰时间(Tmax,ss)
大体时间:末次给药前至末次给药后72小时(连续给药7天)
末次给药前至末次给药后72小时(连续给药7天)
多次给药药代动力学研究:稳态血浆浓度-时间曲线下面积(AUCss)
大体时间:末次给药前至给药后72小时(连续给药7天)
末次给药前至给药后72小时(连续给药7天)
多剂量药代动力学研究:谷浓度
大体时间:末次给药前至给药后72小时(连续给药7天)
末次给药前至给药后72小时(连续给药7天)
多剂量药代动力学研究:蓄积比 (Rac)
大体时间:末次给药前至给药后72小时(连续给药7天)
末次给药前至给药后72小时(连续给药7天)

次要结果测量

结果测量
措施说明
大体时间
不良事件(AEs)发生率
大体时间:最多 16 天
最多 16 天
Change from baseline in hematology parameters: white blood cell count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count , hemoglobin, hematocrit, platelet count
大体时间:up to Day 13

Change from baseline in hematology parameters: white blood cell count (WBC), neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count, red blood cell count (RBC), hemoglobin (Hb), hematocrit (HCT), platelet count (PLT)

up to Day 13
Changes from baseline in serum chemistry parameters
大体时间:up to Day 13

Changes from baseline in serum chemistry parameters: fasting blood glucose (FBG), total protein, albumin, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), blood urea nitrogen (BUN) or urea, uric acid, creatinine, potassium (K⁺), sodium (Na⁺), chloride (Cl-), creatine kinase (CK)

up to Day 13
Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells
大体时间:up to Day 13

Changes from baseline in urinalysis parameters: urine protein, urine ketones, urine glucose, urine pH, urine leukocytes, urine red blood cells (RBCs)

up to Day 13

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月10日

初级完成 (实际的)

2026年10月22日

研究完成 (实际的)

2026年10月25日

研究注册日期

首次提交

2026年3月20日

首先提交符合 QC 标准的

2026年4月1日

首次发布 (实际的)

2026年4月6日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅